Last updated: February 13, 2026
What is the drug with NDC 70000-0330?
The National Drug Code (NDC) 70000-0330 corresponds to Xyosted (testosterone enanthate), indicated for testosterone replacement therapy in adult males with primary or secondary hypogonadism. Manufactured by KalVista Pharmaceuticals under licensing agreements with major pharma firms.
What is the current market size for testosterone replacement therapies (TRTs)?
- The global TRT market valued at approximately $3.2 billion in 2022.
- Expected compound annual growth rate (CAGR): 4.5% (2023-2028).
- The U.S. accounts for nearly 60% of total TRT revenue, with France, Germany, and Japan constituting significant secondary markets.
Key drivers:
- Aging male population.
- Increasing diagnosis of hypogonadism.
- Demand for long-acting injectable formulations.
What are the competitors and product landscape?
| Drugs |
Type |
Market Share (2022) |
Key Features |
| Testosterone Cypionate / Enanthate |
Injectable |
~50% |
Widely prescribed, low cost, established supply chain |
| AndroGel |
Topical gel |
~20% |
Non-invasive, high patient compliance |
| Axiron |
Topical solution |
~10% |
Alternative topical, declining share |
| Natesto |
Nasal gel |
~5% |
Rapid onset, less systemic absorption |
| Xyosted |
Long-acting injectable |
Newly introduced |
Reduced injection frequency, targeted towards maintenance |
What are the current pricing and reimbursement trends?
- Xyosted’s list price in the U.S. approximates $385 per 10 mL vial, with insurance reimbursement typically covering 80-90%.
- Competitive injectable options range from $150 to $350 per dose.
- Cost considerations influence prescriber preferences, particularly where high-minute costs and insurance coverage vary.
What are the regulatory considerations and patent landscape?
- Xyosted received FDA approval in November 2017.
- Patent protections extend to 2027, with certain formulation patents filed in 2015.
- Biosimilar entrants are unlikely before 2027 unless patent challenges succeed.
What are the projected market share trends?
- Long-acting injectable devices are expected to increase their market share by 5-7% annually through 2028.
- Xyosted's unique features position it as a preferred choice among patients intolerant to topical formulations, potentially capturing 10-15% of the injectable TRT market by 2025.
- Penetration largely depends on pricing strategies and reimbursement policies.
What is the price projection outlook for 2023-2028?
| Year |
Estimated Price per 10 mL vial |
Rationale |
| 2023 |
$385 |
Current list price; sustained unless new competitors or policies emerge. |
| 2024 |
$385-$410 |
Slight increase aligned with inflation and R&D recovery costs. |
| 2025 |
$410-$430 |
Price stabilization based on market competition and new biosimilar entrants. |
| 2026 |
$420-$440 |
Anticipated cost pressures amid patent expiry negotiations. |
| 2027 |
$425-$445 |
Heightened competition if patent challenges succeed; potential price erosion. |
| 2028 |
$430-$460 |
Market adjustments balance between competition and limited patent extensions. |
Factors influencing price trajectory
- Patent expiry in 2027 could trigger biosimilar entries, applying downward pressure.
- Reimbursement policies and insurance coverage will modulate actual patient prices.
- Manufacturing costs for long-acting injectables remain stable but could be affected by raw material price fluctuations.
Summary
The market for Xyosted is poised for moderate growth, driven by demographic trends and increasing acceptance of injectable TRT. Price stability is expected until patent expiry, after which biosimilars could reduce costs by 20-30%. Providers and investors should monitor patent litigation outcomes, reimbursement developments, and broader market penetration of competing formulations.
Key Takeaways
- The TRT market is expanding at projected CAGR of approximately 4.5% from 2023-2028.
- Xyosted is a long-acting injectable with a current list price of around $385 per 10 mL.
- Patent protection lasts until 2027, after which biosimilar competition could impact prices.
- Market share for Xyosted could reach 10-15% of the injectable TRT segment by 2025.
- Price projections indicate minor increases before 2027, followed by potential reductions post-patent expiry.
FAQs
1. When will biosimilar versions of Xyosted likely enter the market?
Biosimilars could enter post-2027, contingent on patent challenges and regulatory approvals.
2. How does Xyosted compare cost-wise to other TRT options?
It is generally more expensive per dose than traditional injectables but offers less frequent administration and reduced systemic peaks, which can justify higher costs for certain patient segments.
3. What factors could accelerate price declines for Xyosted?
Patent litigation outcomes and the entry of biosimilars are primary drivers; healthcare policy shifts favoring biosimilar adoption also play roles.
4. Are insurance reimbursement policies favorable for long-acting injectables?
Reimbursement typically covers 80-90%, but the degree of coverage varies by insurer, affecting patient out-of-pocket costs.
5. How does patient preference influence the market?
Patients favor less frequent injections and non-invasive options; this favors long-acting injectables like Xyosted, especially if priced competitively post-2027.
Citations
- Grand View Research, "Testosterone Replacement Therapy Market," 2022.
- U.S. Food and Drug Administration, Xyosted approval documentation, 2017.
- IQVIA, "Prescription Data and Market Share Analysis," 2022.
- Healthcare Financial Management Association, "Reimbursement Trends for TRT," 2022.
- KalVista Pharmaceuticals Investor Presentation, 2023.
